E
Caribou Biosciences, Inc.
CRBU
$0.79
$0.03264.30%
E
Sell
2/10/2025Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D- on 2/10/2025 due to a large decline in the growth index, solvency index and volatility index. Total revenue declined 41.57% from $3.46M to $2.02M, and the quick ratio declined from 8.55 to 7.18.
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D- on 2/10/2025 due to a large decline in the growth index, solvency index and volatility index. Total revenue declined 41.57% from $3.46M to $2.02M, and the quick ratio declined from 8.55 to 7.18.
D
Sell
10/14/2024Upgraded
Caribou Biosciences, Inc. (CRBU) was upgraded to D- from E+ on 10/14/2024 due to an increase in the growth index and valuation index. Total revenue increased 42.61% from $2.43M to $3.46M, operating cash flow increased 11.66% from -$37.2M to -$32.87M, and earnings per share increased from -$0.4617 to -$0.4173.
Caribou Biosciences, Inc. (CRBU) was upgraded to D- from E+ on 10/14/2024 due to an increase in the growth index and valuation index. Total revenue increased 42.61% from $2.43M to $3.46M, operating cash flow increased 11.66% from -$37.2M to -$32.87M, and earnings per share increased from -$0.4617 to -$0.4173.
E
Sell
5/29/2024Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D- on 5/29/2024 due to a decline in the growth index and volatility index. Operating cash flow declined 74.02% from -$21.38M to -$37.2M, total revenue declined 31.73% from $3.56M to $2.43M, and EBIT declined 22.86% from -$37.44M to -$46M.
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D- on 5/29/2024 due to a decline in the growth index and volatility index. Operating cash flow declined 74.02% from -$21.38M to -$37.2M, total revenue declined 31.73% from $3.56M to $2.43M, and EBIT declined 22.86% from -$37.44M to -$46M.
D
Sell
8/3/2023Upgraded
Caribou Biosciences, Inc. (CRBU) was upgraded to D- from E+ on 8/3/2023 due to an increase in the total return index and volatility index.
Caribou Biosciences, Inc. (CRBU) was upgraded to D- from E+ on 8/3/2023 due to an increase in the total return index and volatility index.
E
Sell
3/14/2023Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D on 3/14/2023 due to a decline in the growth index, solvency index and total return index. EBIT declined 15.23% from -$26.54M to -$30.58M, the quick ratio declined from 10.35 to 8.97, and operating cash flow declined 11.92% from -$22.38M to -$25.04M.
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D on 3/14/2023 due to a decline in the growth index, solvency index and total return index. EBIT declined 15.23% from -$26.54M to -$30.58M, the quick ratio declined from 10.35 to 8.97, and operating cash flow declined 11.92% from -$22.38M to -$25.04M.
D
Sell
2/23/2023Upgraded
Caribou Biosciences, Inc. (CRBU) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
Caribou Biosciences, Inc. (CRBU) was upgraded to D from D- on 2/23/2023 due to an increase in the valuation index.
D
Sell
2/8/2023Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 11.98 to 10.35.
Caribou Biosciences, Inc. (CRBU) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 11.98 to 10.35.
D
Sell
5/16/2022Upgraded
Caribou Biosciences, Inc. (CRBU) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
Caribou Biosciences, Inc. (CRBU) was upgraded to D from E+ on 5/16/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index, valuation index and total return index. The quick ratio declined from 14.87 to 13.49.
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D on 5/13/2022 due to a decline in the solvency index, valuation index and total return index. The quick ratio declined from 14.87 to 13.49.
D
Sell
5/4/2022Upgraded
Caribou Biosciences, Inc. (CRBU) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Caribou Biosciences, Inc. (CRBU) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index and volatility index.
D
Sell
4/21/2022Upgraded
Caribou Biosciences, Inc. (CRBU) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
Caribou Biosciences, Inc. (CRBU) was upgraded to D from E+ on 4/21/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index, efficiency index and volatility index. Total capital declined 4.1% from $404.4M to $387.83M.
Caribou Biosciences, Inc. (CRBU) was downgraded to E+ from D on 4/20/2022 due to a significant decline in the total return index, efficiency index and volatility index. Total capital declined 4.1% from $404.4M to $387.83M.
D
Sell
12/10/2021Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to D from D+ on 12/10/2021 due to a large decline in the volatility index and total return index.
Caribou Biosciences, Inc. (CRBU) was downgraded to D from D+ on 12/10/2021 due to a large decline in the volatility index and total return index.
D
Sell
11/26/2021Downgrade
Caribou Biosciences, Inc. (CRBU) was downgraded to D+ from C- on 11/26/2021 due to a decline in the volatility index and total return index.
Caribou Biosciences, Inc. (CRBU) was downgraded to D+ from C- on 11/26/2021 due to a decline in the volatility index and total return index.
C
Hold
11/11/2021Upgraded
Caribou Biosciences, Inc. (CRBU) was upgraded to C- from D+ on 11/11/2021 due to a substantial increase in the solvency index, growth index and efficiency index. Total capital increased 294.7% from $102.46M to $404.4M, the quick ratio increased from 5.3 to 16.94, and total revenue increased 169.44% from $1.48M to $3.98M.
Caribou Biosciences, Inc. (CRBU) was upgraded to C- from D+ on 11/11/2021 due to a substantial increase in the solvency index, growth index and efficiency index. Total capital increased 294.7% from $102.46M to $404.4M, the quick ratio increased from 5.3 to 16.94, and total revenue increased 169.44% from $1.48M to $3.98M.
D
Sell
11/3/2021Upgraded
Caribou Biosciences, Inc. (CRBU) was upgraded to D+ from D on 11/3/2021 due to a substantial increase in the total return index.
Caribou Biosciences, Inc. (CRBU) was upgraded to D+ from D on 11/3/2021 due to a substantial increase in the total return index.
D
Sell
10/15/2021None
Caribou Biosciences, Inc. (CRBU) was downgraded to D from U on 10/15/2021.
Caribou Biosciences, Inc. (CRBU) was downgraded to D from U on 10/15/2021.
NASDAQ
04/08/2025 4:00PM Eastern
Quotes delayed
